Lasers in the Treatment of Vitiligo by Turan, Isil Kamberoglu
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Lasers in the Treatment of Vitiligo
Isil Kamberoglu Turan
Abstract
Vitiligo is an acquired cutaneous hypopigmentary disorder characterized by 
multiple depigmented macules and patches. There are numerous therapy modalities 
consist of topical corticosteroids and calcineurin inhibitors, phototherapy, surgi-
cal interventions and laser treatments are evaluated. Last 10 years, firstly excimer 
laser treatment has showed good results in repigmentation rates. “Excited dimers” 
produces a 308-nm ultraviolet (UV) monochromatic coherent wavelength, which 
lies within the UVB spectrum that absorb DNA as a chromophore to breakage DNA 
chain that causes a decrease in T-lymphocyte proliferation. Some articles have 
shown different responses depends on the type of vitiligo, number of sessions, 
interval periods and localisation. Researchers have also compared efficacy and 
also side effects of excimer laser between other methods. Combination therapies 
with excimer laser will be also treatment of choice via topical steroids or topical 
calcineurin inhibitors. Some of the patients developed delayed-onset permanent 
hypopigmentation need resurfacing methods such as CO2 or Er:YAG laser which 
mainly aims to ablate the epidermis in specific coagulation columns to promote 
the penetration of externally applied agent. As an alternative treatment modality 
in vitiligo, lasers may help to raise patient compliance and reduce potential risk for 
skin cancer. Its convenience is limited by high cost and accessibility.
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1. Introduction
Vitiligo is an autoimmune skin disorder with a 0.5–2.0% incidence worldwide 
without sex or age. It is characterized by hypopigmented macules and patches 
due to dysfunction of melanocytes. Etiology of the disease could not elucidated 
yet. The significant association between vitiligo and other autoimmune diseases, 
including alopecia areata, diabetes mellitus, Addison’s disease, pernicious anemia, 
Graves’ disease, Hashimoto’s thyroiditis, systemic lupus erythematosus, rheuma-
toid arthritis, psoriasis and inflammatory bowel disease. Vitiliginous patches are 
often psychologically distressing and also have risk to loss of social status so that 
they cause negative impact of quality of life index. Two major forms are generally 
recognized that are segmental and nonsegmental types. Treatment of vitiligo is chal-
lenging and consensus of treatment modalities have changed beyond the types and 
places where the lesions mainstay. There are various phototherapy treatments which 
consist of PUVA, narrow-band UVB (NUVB), excimer laser and lamp commonly 
based on stimulation of melanocytes in the outer root sheath of hair follicles and 
on the margins of lesions besides that residual intralesional melanocytes migrate 
and repopulate the vitiliginous areas. Topical corticosteroid, calcineurin inhibitors, 
vitamine E and pseudocatalase could combine with these modalities to increase 
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treatment response. Furthermore in stable vitiligo patients, surgical methods such 
as full-thickness tissue graft (punch graft), split thickness graft, and suction blister 
graft, cellular grafts contains cultured melanocytes/keratinocytes have shown 
promising results [1, 2].
2. Laser treatments approach in vitiligo patients
2.1 Excimer laser for immunomodulation in adult vitiligo patients
Monochromatic excimer light was first described for the treatment of psoriasis 
in 1997 and 4 years later Baltás et al. reported the first case of successful use of the 
excimer laser for the treatment of vitiligo in 2001 [3]. In vitiligo patients, the widely 
use narrowband UVB (NUVB) that contains 310–313 nm wavelength has safety 
profile. At that wavelength arrival we can also conduct monochromatic excimer 
laser (MEL) with an obligation of limited skin areas to protect nonlesional apart. 
Mostly clinicians uses 308 nm wavelength according to obtain skin epidermal 
barrier to induce immunotargeted therapy. New concept of era called targeted 
phototherapy is usually recommended for localized forms of vitiligo affecting less 
than 10% of the body surface area. Although these localized modality could prevent 
hyperpigmentation of uninvolved skin, it could not achieve to deprive new lesion 
output. In the literature we do not have so much scientific verifications. In Egypt, 
Eldin et al. analyzed 30 patients with nonsegmental vitiligo with at least two sym-
metrical vitiliginous patches. They treated twice a week for 6 weeks with 308-nm 
MEL and NUVB for 6 weeks these contralateral lesions. Three punch biopsies were 
taken from baseline and 6 weeks later. At the MEL group statistically significant 
rise in the number of basal pigmented cells in the earlier period [4]. According to 
that, MEL would be treatment of choice rather than NUVB because of rapid onset, 
lower cumulative doses and lesser treatment sessions. This study is the only proof of 
histopathological verification for comparison of these proven treatment modalities. 
Narrowband UVB, excimer laser and lamp has spreaded out similar wavelength 
even though they have different radiation properties. Mostly articles have shown 
that excimer laser and lamp have similar repigmentation rate and also minimal side 
effects so that clinicians should decide how to treat due to cost benefit analysis.
Lopes et al. published a metanalysis, they conducted there is no difference 
between repigmentation rate for all three treatment options. 308 nm excimer 
laser has much more safety profile than narrowband UVB because it works lesser 
time without affecting uninvolved skin and also affect deeper skin via change-
able impulse frequency and intensity. However, excimer laser is characterized by 
monochromatic, coherent, and high-energy light, whereas NB-UVB consists of 
polychromatic, incoherent light with lower intensity [5]. Yan et al. declared that 
lesions located on the face and neck had better repigmentation rate with excimer 
lamp controversially extremities have better response with NB-UVB. Le Duff et al. 
observed that the excimer lamp is less expensive than the laser, allowing cost/
effectiveness prolificacy however treatment period has been longer [6]. Sun et al. 
presented a scientifically supportive study such as seven randomized controlled 
trials. They declined that excimer laser has as similar as therapeutic effects with 
lamp and also combination of 308-nm excimer laser with 0.1% tacrolimus or with 
tacalcitol ointment can improve the repigmentation rate [7]. Different responses 
could be based on different angle of UVB-light emission to epidermis via fiber optic 
devices of excimer laser. Mostly, narrowband UVB treatment is used the most effec-
tive for nonsegmental vitiligo, while excimer laser treatment is commonly chosen 
for localized vitiligo by clinicians.
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Efficacy of the excimer laser depends the number of session in a week or total 
cumulative doses. Fitzpatrick skin types of III and above typically respond bet-
ter than lower skin types. As usual, facial, neck and axillary regions have quick 
response opposed to acral parts of body. Clinicians should refer minimal erythema 
dose (MED) and increment arrival differs between 10 and 25%. Frequency of the 
laser did not play a role in pigmentation although rapid onset of treatment depends 
on suitable action plan. Shen et al. determined that time of repigmentation begins 
earlier as same as in 2.0 and 3.0 frequency period than 1.0 but also all of them 
have same pigmentation areas [8]. According to small spot size, these modality is 
not suitable for patients with vitiligo involving large body surface areas (>15%). 
Repigmentation differs site by site consist of perifollicular, diffuse, marginal, and 
combined. The perifollicular pattern was the most common seen.
There is a negative correlation between the duration of the disease and the 
percentage of repigmentation which could be named as unresponsiveness. Topical 
corticosteroids have been a mainstay in vitiligo treatment for decades. However 
refractory vitiligo patients should need combination modalities. As known, topical 
corticosteroids have significant adverse effects such as skin atrophy, striae, erythema, 
acne, increased glucose level, glaucoma. According to that, topical pimecrolimus or 
tacrolimus ointments have been promising for the treatment of choice. Shin et al. 
would like to analyze combination of NUVB and excimer laser to unresponsive 
patients, they also determined that acral lesions are difficult part to treat but com-
bination could be greater choice due to less adverse effect to difficult cases mainly in 
facial vitiligo group [9]. Latif et al. investigated two randomly selected vitiliginous 
patches, first group of lesions had taken combination of excimer laser and betameth-
asone dipropionate and calcipotriol ointment twice daily and second group had taken 
only excimer laser two unconsecutive days in a week for 12 weeks. They concluded 
that in nonsegmental vitiligo lesions treated with topical combination of vitamin D3 
analogue and steroid with 308 nm MEL gave significant results rather than excimer 
laser alone and it could be promising option for the treatment of vitiligo [10]. All 10 
patients who have bilateral symmetric vitiliginous patches received xenon chloride 
excimer laser three times weekly and calcipotriol ointment was applied twice Daily 
one side of the body. While conversely, during the 15th month follow up Goldinger 
et al. compared a combination of excimer laser and calcipotriol with excimer laser 
alone, and found no significant difference between them [11]. Passeron et al. ana-
lyzed the efficacy of combined tacrolimus (twice daily) and 380 nm excimer laser 
(twice a week) or difference of monotherapy. Twenty three lesions had taken excimer 
laser and tacrolimus combination but also 20 lesions had taken laser monotherapy 
and all lesions have similar repigmentation rates such as 100 versus 85%. They deter-
mined that UV-sensitive areas do not have different response rate but in UV-resistant 
areas combination treatment is clearly superior to laser monotherapy via synergistic 
effects [12]. Park et al. have shown that increment at the molecular level of tyrosinase 
and melanin in human melanocytes with combination of excimer laser and tacroli-
mus rather than each monotherapy in the first 6 month. However, this superiority 
was not observed in the patients who treated more than 6 months [13]. Wang et al. 
published an article, all patients received laser therapy twice weekly combined with 
tacrolimus cream twice daily for 12 weeks. Dermoscopy is a useful tool for asses the 
outcome of the laser. They found statistically significant induction of residual perifol-
licular pigmentation and perilesional hyperpigmentation in active disease rather than 
stable disease [14]. Topical antioxidant cream which includes superoxide dismutase 
and catalase activity could combine with excimer laser. Soliman et al. published an 
article the comparison of excimer laser alone and antioxidant cream combination via 
30 patients have similar vitiliginous patches has followed up maximum 24 sessions, 
they found excellent cosmetic results regard minimal side effects [15] Bapur et al. 
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also has propagated topical tacrolimus or topical clobetasol-17 propionate ointment 
enhance the efficacy of excimer laser [16]. As a summary, there is big gap for to 
discuss which topical choice has better results.
In segmental vitiligo patients, excimer laser has claimed as a treatment of choice. As 
a proof, Bae et al. made a treatment schedule that received 20 mg of prednisolone daily 
for the first 3 weeks, twice a week excimer laser and twice a day tacrolimus ointment. 
They found more than half of the patients with segmental vitiligo showed 75% or more 
repigmentation with combination therapy for mean period is 1 year [17]. Jag et al. also 
investigate small sample size, firstly gave low-dose oral prednisolone (0.3 mg/kg/day) 
for 4–8 weeks, 0.1% topical tacrolimus twice daily, and excimer laser twice a week for 
12 weeks. They found higher response rate rather than current therapies [18].
Bae et al. evaluated 311 Titanium-Sapphire Laser (TSL) Treatment in vitiligo 
that based on 14 patients with non-segmental vitiligo are treated with TSL twice 
a week. They determined working principle as similar as NUVB an EL by immu-
nomodulation and melanocyte stimulation. Main advantage is not necessary to 
check gas charging and also penetrate deeper than 308 nm wavelength of excimer 
laser [19].
BinSheikan et al. suggested a surgical needling technique means 30 Gauge 
inserted almost parallel to the skin surface towards the dermoepidermal junction 
moving towards the pigmented site to depigmented skin could increase the efficacy 
of excimer laser [20]. Mutairi et al. reported that combination of split-skin grafting 
from normal skin to vitiligo part with excimer laser twice a week have long-lasting 
good results in stable vitiligo patients. All of them satisfied to treatment and 
respond excellent as well [21].
Leukotrichia also called poliosis mainstays white hair involving the scalp, 
eyebrows, and pubis has frequently seen together with segmental vitiligo. Kim et al. 
evaluated the effect of the presence of leukotrichia on the response to excimer laser 
therapy at the first time and they suggested that leukotrichia has poor response 
due to lack of melanocyte reservoir. They also did not find any difference between 
vitiligo types [22]. All in all, disease duration longer than 12 months, presence of 
leukotrichia and plurisegmental subtype were identified to be independent poor 
prognostic factors for excimer laser treatment.
Adverse effects of treatments are mild and acceptable which are pruritus, 
burning sensation, and dryness. MEL has a favorable risk-to-benefit ratio which has 
only minimal side effects are mainly acute and self-limited phototoxicity especially 
erythema does not persist longer than 24 hours. Furthermore another local site 
effects are tolerable that consist of blisters, itching or perilesional pigmentation but 
do not seen frequently.
If the patient does not improve meanly after 30 sessions twice or three times weekly, 
it is suggested that further treatment could provide any significant response [23].
Dermatology quality of life index (DLQI) scale could provide us convenient and 
important data for benefits of the treatment. It occasionally contained validated 
questionnaires such as symptoms and feelings, daily activities, leisure, work and 
school, personal relationships and treatment. In some analysis reports has con-
cluded that long duration of disease, hand and face lesions and female patient have 
greater impairment of life index but also Shobaili et al. has shown that excimer laser 
has better improvement in quality of life index [25]. Alghamdi et al. made a survey 
in Saudi Arabia to prove dermatologists’ clinical assessment for vitiligo treatment. 
They found excimer laser was the most common modality used to treat focal and 
segmental vitiligo and occasionally used in private clinics [26].
Excimer laser treatments respond faster recovery period and induce repigmenta-
tion rate so that clinicians use fewer treatments with less cumulative dose in order 
to achieve repigmentation compared with traditional phototherapy. The best result 
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is noticed on UV-sensitive areas and also does not affect unlesional part of the body 
regard as the face and neck; whose has shorter history of vitiligo. Combination with 
topical steroid or topical calcineurin inhibitor (tacrolimus and pimecrolimus) increases 
the efficacy. The excimer laser has proven to be a useful tool in the treatment of vitiligo.
2.2 Excimer laser in child vitiligo patients
NBUVB is a safe and effective, well-tolerated treatment option for childhood 
vitiligo as well as for vitiligo in adults declared as a treatment of choice. Besides 
the adult population, children who has vitiligo also treated with excimer laser 
that based on xenon chloride lasers has been delivering radiation of 308–310 nm, 
with a variable spot size. Acral regions, resistant areas, hidden places are favor-
able for excimer laser. Gianfaldoni et al. determined treatment schedule should 
consist of twice weekly among 13 weeks to achieve good response [27]. Clinicians 
should estimate minimal erythema dose (MED) and begin with 10% lesser than it. 
Occasionally, face and neck has responded well but acral lesions has repigmented 
slowly. Cho et al. suggested that treatment response rate has correlated with ana-
tomic site of the vitiligo lesion especially in localized type [28].
2.3 UVA1 target laser in children
Another optional treatment modality could regard as UVA1 target laser consists 
of an active medium and a Neodymium-doped yttrium orthovanadate (Nd:YVO4) 
crystal that is “energetically pumped” by another laser with 808 nm wavelength 
divided sequentially second (532 nm) and third (355 nm) harmonic wavelength 
delivery. Laser Alba allows the treatment of limited boarded lesional skin areas so 
that clinician can use a more appropriate dose of energy, leading to shorter dura-
tion and less frequent treatment sessions. The treatment with Laser Alba 355 is 
well—tolerated and already known acute side effects, such as erythema or pruritus 
have rarely been described.
Furthermore, innovative modalities consist of excimer laser, focused micropho-
totherapy and also Laser ALBA should investigate to create new options [27, 29].
2.4 Fractional CO2 laser for ablation modalities
As you know, vitiligo therapy is challenging though there is no definitive cure 
regime. Ablation therapy has recently been coalesced into combination therapy for 
vitiligo. These ablation modalities contains dermabrasion, erbium-YAG resurfac-
ing, and ablative CO2 laser treatment. Ablation modalities are not curative but they 
are useful to induce Koebner phenomenon to increase curative topical regimes. 
Fractional ablative laser has worked as a principle of photothermolysis to moder-
ate skin resurfacing. Firstly, beneficial effect of fractional CO2 laser on vitiligo is 
postulated to detachment of epidermis will release of cytokines and growth factors 
for immune response that plays a role as mitogens for melanogenesis. Additionally, 
fractional CO2 laser via photothermolysis could decrease to skin surface so that 
absorb topical treatments and also increase efficacy of narrowband UVB treatment. 
Koebner’s phenomenon defined as the development of isomorphic lesions at trau-
matized uninvolved skin due to that fractional modalities to be concluded follicular 
hyperpigmentation as a different addition for pathogenesis. King et al. published a 
metanalysis, they determined ablation modalities (ER-YAG or fractional CO2 laser) 
manage faster and effective repigmentation than the traditional methods that have 
explained via four different such as more penetration, skin remodeling, melano-
cyte migration and cytokine secretion [30]. Despite of that Koebner phenomenon 
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has not seen in stable lesions so that individual remedy should be chosen. In a 
recent article Yuan et al. aim to investigate three different fractional laser types. 
Ablative fractional laser consist of CO2 lasers have much more satisfied results than 
non-ablative lasers [31]. On the contrary, Mofty et al. evaluated that TCA peel-
ing depends on Koebner phenomenon redounded repigmentation is much more 
cheap, easier and effective than ablative CO2 laser [32]. Lu Li et al. has tried differ-
ent model with CO2 laser. They applied sequentially CO2 laser during half month 
interval and used twice daily betamethasone then took NUVB. They checked the 
response rate at the baseline, 3th and 6th month and also found repigmentation 
more than half of the patients to compare without betamethasone ointment. They 
suggested patient got tolerable pain and gain more satisfied repigmentation rate 
than ER YAG laser is expected [33]. Helou et al. concerned a different modality 
contains CO2 laser three times 1 month apart following that sunlight tanning at least 
2 hours has also significant results. These different opinions will be future play as 
an easy to apply due to cost-benefit analysis [34]. Nevertheless, there is no defined 
protocol for ablation to stimulate melanocyte transmission.
More advanced ablation modalities could combine with other topical remedies 
to optimize results. Feily et al. comprised two group stable refractory vitiligo 
patients got autologous transplantation and phototherapy alone or with fractional 
CO2 laser. They found perifollicular repigmentation was statistically significant 
detectable in CO2 laser group before the transplantation [35]. Vachiremon et al. 
suggested that fractional ablative CO2 laser could combine with NUVB to shorten 
duration time of recovery and increase the penetration of light immunomodula-
tion and also topical clobetasol propionate ointment [36]. Additionally that, acral 
part could not reach the treatments so that alternatives should try. By using CO2 
laser, clinicians have seen lesser hypertrophic scars than ERYAG laser also so that 
treatment of choice in ablative lasers could manifested. Mohamed et al. searched 
the combination of 5-Fluorouracil cream and CO2 laser due to ablation of der-
mis to penetrate cream to migrate melanocytes in acral vitiligo patients. They 
declined that combination treatment is safe and tolerable technique for these 
resistant types [37]. Chen et al. investigated the topical tacrolimus combination 
with CO2 laser, they suggested tacrolimus would be good option with ablation 
therapies, also [38]. Using with CO2 laser, hypertrophic scarring was not reported 
because of the superficial ablation that means removing only the epidermis, 
avoiding the dermis.
As a summary, ablation-based combination therapy is safe and might be more 
effective than treatments without ablation therapy for increment of repigmentation.
2.5 Erbium laser for ablation modalities
The Er:YAG laser emits light at 2940 nm, with the water affinity being nearly 15 
times greater than that of the CO2 laser. Use of the Er:YAG laser requires more skill 
than does use of the CO2 laser as the clinical endpoints allowing the laser surgeon 
require to intervene further penetration into the reticular dermis, are not seen with 
Er:YAG laser ablation. Furthermore, the plateau response of diminishing ablation 
characteristic of the CO2 laser is not seen with the Er:YAG laser [1, 24]. Lotti et al. 
used a different innovation in a ablative model with Fraxel Erbium Laser (fractional 
erbium laser) make epidermal erosion 1 day after apply topical latanoprost solu-
tion and finally use UVA laser. The patients have nine sessions so on 90% of them 
obtained a repigmentation rate higher than 75% [39]. Bayoumi et al. tried to use 
erbium laser firstly for aiming dermabrasion after that 48 hours hydrocortisone 
17-butyrate cream applied three times a day daily for 3 weeks followed by a 1-week 
steroid-free interval and narrowband UVB treatment was performed on both sides 
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twice weekly for 12 weeks. They succeed in refractory lesions due to Koebner’ 
phenomenon almost half of the lesions treated at least 50% repigmentation rate and 
more than 16% achieved a complete or almost complete repigmentation [40]. As 
a point of view, that difference from non-treated part, dermabrasion has induced 
penetration of UVB and topical steroid so it cause enhancement of melanocyte 
stimulation. For example Yan et al. have a different perspective they insisted on 
energy should be set at the level of at least 1200 mJ. They divided four parts such 
as one of them is control group given NUVB and other three of them took different 
frequency of energy to calibrate most effective and least painful method of these 
modality. They found better response at the medium or high energy protocols [41]. 
Mohtari et al. tried to find a unresponsiveness vitiligo part a new modality that is 
firstly used ER:YAG laser than applied clobetasol or 5-FU dressing and found better 
cosmetic results via ablation [42]. As expected, periungual vitiligo hard places 
to treat responded well. Two-thirds of the patients (66.7%) showed moderate to 
marked repigmentation via ER:YAG after dressing 5-FU [43].
On the whole, the acral regions were considered the most resistant to traditional 
treatment modalities. According to that, ER:YAG laser with topical corticoid, 
tacrolimus or 5-FU application could be promising treatment modality for unre-
sponsiveness patients.
2.6 Q-switch laser for depigmentation modalities
Depigmentation is the unique treatment choice who develop vitiligo more than 
90% body surface area, for the term “universal vitiligo” is commonly used. Topical 
agent such as MBEH (monobenzyl ether of hydroquinone) has main role to epider-
mal ablation and resurfacing. Laser therapies depend on therapies via difference to 
intact areas such as epidermal and dermal types. Specifically, Q switch laser could 
achieve faster depigmentation compared with chemical agents and the decrease the 
risk of scar formation. Q-switched Nd:YAG (QS ND:Yag) laser can deliver energy at 
two different wavelengths of 1064 and 532 nm in nanosecond pulses to cause both a 
photothermolytic and photoacoustic damage to melanocytes [1, 24].
Majid et al. followed up 15 patients covered more than 80% depigmentation 
areas whole body who have not respond MBEH least 3 months, They focused 
on Q-switch laser at 532 nm for epidermal component for need any session took 
6th week arrival while continuing MBEH topical agents use has rapid onset 
improvement and minimal adverse effect [44]. Komen et al. has published a 
questionnaire about the result of Q switch (QS) Ruby laser that concluded 48% 
of the treated patients showed >75% depigmentation after a mean of 13 months’ 
follow-up. This is the first study that comparison between active vitiligo during 
QS Ruby laser treatment have properly better results than stable vitiligo [45]. 
As a choice of MBEH, sometimes, the depigmentation site has gave up to fight 
immune system and looked more darker so that clinicians has to improve concen-
tration. Modi et al. rather to use 532-nm Q-switched neodymium-doped yttrium 
aluminum garnet (QS Nd:Yag) laser via 2 sessions with 15 weeks intervals have 
good results. They offer to give 3 or 4 months apart to allow for maximal treat-
ment response [46]. Majid et al. has followed up 25 patients with universal 
vitiligo from 2 to 5 years and determined QS-Nd:Yag laser leads to a long-term 
therapeutic effect in a majority of cases when used at 532-nm wavelength. Less 
than one third of cases during the follow-up period could preserve the therapeu-
tic benefit achieved with laser treatment [47]. Boukari et al. has followed patients 
for 36 months depigmented 20 lesions via Q Switch laser and determined that 
risk of depigmentation parts mainstays in sun exposed areas have need mainte-
nance therapies [48].
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In conclusion, QS Nd:YAG laser at 532-nm wavelength seems to be a safe and 
effective treatment in depigmenting approach to universal vitiligo. The safety and 
long-term benefit achieved should qualify QS laser treatment as first-line treatment 
who did not respond topical bleaching creams. Moreover, QS laser combine with 
topical bleaching creams and sunscreen use, can achieve rapid satisfactory thera-
peutic outcome in universal vitiligo.
3. Conclusion
Vitiligo is a difficult disease to treat because of that new modalities should be 
investigated. As you known, traditional remedies such as NUVB and topical corti-
costeroids or tacrolimus did not respond well than new era has developed a concept 
called targeted phototherapy. Regarded as a targeted phototherapy excimer laser 
has same wavelength as same as NUVB to focused on apoptosis of T lymphocytes. 
However, excimer laser is characterized by monochromatic, coherent, and high-
energy light, whereas NB-UVB consists of polychromatic, incoherent light with 
lower intensity. Excimer laser has significant safety profile and got better results 
than NUVB so that clinicians should decide the option to evaluate cost benefit 
analysis. Other traditional topical remedies could also apply with excimer laser to 
induce effectiveness. In segmental vitiligo patients or child population, excimer 
laser could be treatment of choice also due to localized areas. Another point of 
view of the laser treatment is ablation. Using the Koebner phenomenon, CO2 laser 
and ER:YAG have worked as a principle of photothermolysis to moderate skin 
resurfacing. Traditional remedies could also combine with ablative laser types to 
increase the absorption of the treatments. Clinicians further to analyze depig-
mentation need. If patient has more than 80% depigmented areas, Q switch laser 
combine with topical bleaching creams and sunscreen use, can achieve rapid sat-
isfactory therapeutic outcome in universal vitiligo. Vitiligo does not have a steady 
all known treatment protocols even though clinicians should further to investigate 
new combinations.
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